Medifirst Solutions Appoints New CEO

Rhea-AI Summary

Medifirst Solutions (OTC PINK:MFST) announced the appointment of Thomas Griffin as CEO, succeeding in leadership with over 25 years of global entrepreneurial experience. Griffin, recognized for his role in the aviation and finance sectors, is focused on steering the company towards profitability and growth. He aims to redefine the company's future while leveraging recent FDA clearance for the Time Machine TTML-8102000 Laser, designed for pain relief and muscle relaxation. The device promises immediate results with minimal side effects, opening new revenue opportunities for medical professionals.

Positive

• Appointment of Thomas Griffin as CEO could bring fresh leadership and strategic direction.
• FDA clearance for the Time Machine TTML-8102000 Laser enhances product offerings in pain management.

Negative

• Transition to a new CEO may disrupt existing operations or strategy continuity.

FREEHOLD, NJ / ACCESSWIRE / June 30, 2021 / MEDIFIRST SOLUTIONS, INC. (OTC PINK:MFST) (the 'Company' or 'Medifirst') is pleased to announce naming Thomas Griffin as the Company's CEO. In the last 25 years, Mr. Griffin has been a global entrepreneur with proven success, a seasoned advisor and investor; a well-respected aviation, finance and business development executive. He places emphasis on profitability and growth which his partners and stakeholders trustfully embrace. In 2019, he was awarded with 'Pioneer Award' by the '5th China Capital Forum.' Mr. Griffin has recently relocated back to the US from Asia.

Mr. Griffin stated: "I am eager to take on this challenge, and over the next several weeks I will be considering how to put the company's past in the past, where to take it to create a profitable future, and how to get it quickly into that future."

About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for 'The Time Machine' Series Laser, received clearance from the U.S. Food and Drug Administration ('FDA') to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer.

Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Medifirst Solutions, Inc.

Investor Relations
medifirstsolutions.ir@gmail.com

SOURCE: Medifirst Solutions, Inc.

View source version on accesswire.com:
https://www.accesswire.com/653770/Medifirst-Solutions-Appoints-New-CEO

FAQ

What is the significance of Thomas Griffin's appointment as CEO of MFST?

Thomas Griffin's appointment as CEO is significant as he brings extensive experience in entrepreneurship and business development, which may lead to improved profitability and growth for MFST.

What is the Time Machine TTML-8102000 Laser approved by the FDA?

The Time Machine TTML-8102000 Laser is an FDA-cleared device intended for temporary relief of muscle and joint pain, enhancing treatment protocols for medical professionals.

What are the expected impacts of the new CEO on Medifirst Solutions?

The new CEO is expected to provide fresh perspectives and strategies to drive profitability and navigate the company's future direction.

Why did Medifirst Solutions appoint a new CEO at this time?

The appointment of a new CEO comes as the company seeks to move past previous challenges and establish a profitable growth strategy.

How does the FDA clearance affect Medifirst Solutions' business prospects?

FDA clearance for the Time Machine Laser positions Medifirst Solutions to expand its market offerings, potentially increasing revenue through enhanced treatment solutions.